Content Type: Policy Interactions

Testimony: Why Are Some Generic Drugs Skyrocketing in Price?

April 8, 2026

Testimony in Support of H.866: an Act Relating to Prescription Drug Manufacturer Cost Transparency

April 8, 2026

Testimony on the Impact of S.1048: A Bill to Improve Transparency of Drug Research and Development Costs

April 8, 2026

Testimony in Support of Legislation on Pharmaceutical Transparency and Price Gouging

April 8, 2026

Testimony on the Impact of S.706/H. 1333: An Act to Ensure Prescription Drug Cost Transparency and Affordability

April 8, 2026

Testimony: High Drug Prices in the US: What We Can Learn From Other Countries and Some US States

April 8, 2026

Testimony: Taxpayers Paid Billions for It: So Why Would Moderna Consider Quadrupling the Price of the COVID Vaccine?

April 8, 2026

Testimony in Support of Prescription Drug Price Transparency and Disclosure Legislation (SB 445)

April 8, 2026

Testimony in Support of Prescription Drug Price Transparency and Disclosure Legislation (SB 925)

April 8, 2026

Comments on Draft Guidance, “Expedited Program for Serious Conditions-Accelerated Approval of Drugs and Biologics”

March 17, 2026

Comments on Draft Guidance, “Accelerated Approval and Considerations for Determining Whether a Confirmatory Trial Is Underway”

March 17, 2026

Comments for Listening Session, “Joint USPTO-FDA Collaboration Initiatives” (Tu)

March 17, 2026